On Aug. 21, 2019, the Siteman Cancer Center announced it was awarded a $15 million grant to better understand the genetic changes that drive acute myeloid leukemia (AML), a deadly blood cancer, and predict patients’ responses to therapy.

The findings also may enable investigators to develop more effective therapies tailored to patients, based on the genetic characteristics of their cancer cells.